Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation

Immune-mediated colitis is an uncommon but well-documented adverse event in patients receiving nivolumab or ipilimumab therapy. In this report, we present a 69-year-old man who developed severe hypokalemia and colitis with significant corrected Q-T segment (QTc) prolongation as a result of combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Anson, David, Norton, Joseph, Chaucer, Benjamin, Bansal, Saurabh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948332/
https://www.ncbi.nlm.nih.gov/pubmed/31949966
http://dx.doi.org/10.1155/2019/7896749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948332/
https://www.ncbi.nlm.nih.gov/pubmed/31949966
http://dx.doi.org/10.1155/2019/7896749

Ejemplares similares